Information Provided By: 
Fly News Breaks for May 17, 2018
NVS, AMGN
May 17, 2018 | 20:54 EDT
Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $190 price target on Amgen (AMGN) after today's FDA approval of Aimovig in migraine. The analyst notes that this marks the first anti-CGRP therapy approval in what is expected to be a crowded space, adding that Amgen and its partner Novartis (NVS) have "effectively capitalized on their first-mover advantage." The analyst says the smart pricing for the product should allow this launch to "beat expectations".
News For AMGN;NVS From the Last 2 Days
There are no results for your query AMGN;NVS
